1. Home
  2. ZJYL vs SRPT Comparison

ZJYL vs SRPT Comparison

Compare ZJYL & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZJYL
  • SRPT
  • Stock Information
  • Founded
  • ZJYL 2006
  • SRPT 1980
  • Country
  • ZJYL China
  • SRPT United States
  • Employees
  • ZJYL N/A
  • SRPT N/A
  • Industry
  • ZJYL Industrial Specialties
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZJYL Consumer Discretionary
  • SRPT Health Care
  • Exchange
  • ZJYL Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • ZJYL N/A
  • SRPT N/A
  • IPO Year
  • ZJYL 2023
  • SRPT 1997
  • Fundamental
  • Price
  • ZJYL $0.80
  • SRPT $37.74
  • Analyst Decision
  • ZJYL
  • SRPT Buy
  • Analyst Count
  • ZJYL 0
  • SRPT 23
  • Target Price
  • ZJYL N/A
  • SRPT $125.43
  • AVG Volume (30 Days)
  • ZJYL 176.8K
  • SRPT 5.9M
  • Earning Date
  • ZJYL 07-25-2025
  • SRPT 05-06-2025
  • Dividend Yield
  • ZJYL N/A
  • SRPT N/A
  • EPS Growth
  • ZJYL 18.46
  • SRPT N/A
  • EPS
  • ZJYL 0.02
  • SRPT N/A
  • Revenue
  • ZJYL $23,502,010.00
  • SRPT $2,233,371,000.00
  • Revenue This Year
  • ZJYL N/A
  • SRPT $39.01
  • Revenue Next Year
  • ZJYL N/A
  • SRPT $13.35
  • P/E Ratio
  • ZJYL $31.97
  • SRPT N/A
  • Revenue Growth
  • ZJYL 18.57
  • SRPT 59.15
  • 52 Week Low
  • ZJYL $0.56
  • SRPT $34.10
  • 52 Week High
  • ZJYL $4.38
  • SRPT $173.25
  • Technical
  • Relative Strength Index (RSI)
  • ZJYL 50.46
  • SRPT 33.74
  • Support Level
  • ZJYL $0.60
  • SRPT $36.96
  • Resistance Level
  • ZJYL $0.81
  • SRPT $39.56
  • Average True Range (ATR)
  • ZJYL 0.07
  • SRPT 2.06
  • MACD
  • ZJYL -0.00
  • SRPT 0.98
  • Stochastic Oscillator
  • ZJYL 68.97
  • SRPT 36.26

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: